Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

ClinicalTrials.gov ID: NCT04913675

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04913675. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 7:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Multi-center, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Monoclonal Antibody VIR-7831 (Sotrovimab) Given Intramuscularly Versus Intravenously for the Treatment of Mild/Moderate Coronavirus Disease 2019 (COVID-19) in High-risk Non-hospitalized Patients; Safety Substudy Assessing the Safety and Tolerability of Single Ascending Dose Monoclonal Antibody VIR-7831

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The COMET-TAIL main study evaluated efficacy, safety, and tolerability of IM sotrovimab versus IV sotrovimab in high-risk patients for the treatment of mild/moderate COVID-19. In the safety substudy, the aim was to evaluate the safety and tolerability of sotrovimab across a single ascending dose level and over different infusion times when given for the treatment of mild/moderate COVID-19 to participants at high risk of disease progression Main study was completed successfully. The safety sub-study was discontinued early in the context of evolving variants with increased fold changes in the in vitro half maximal inhibitory concentration (IC50) and uncertainty in the clinical relevance of these changes.

Study identification

NCT ID
NCT04913675
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Vir Biotechnology, Inc.
Industry
Enrollment
1,065 participants

Conditions and interventions

Conditions

Interventions

Biological

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 10, 2021 (Actual)
Primary completion
Jul 19, 2022 (Actual)
Completion
Mar 24, 2023 (Actual)
Last update posted
Mar 7, 2024

2021 – 2023

United States locations

U.S. sites
48
U.S. states
15
U.S. cities
34
Facility City State ZIP Site status
Investigative Site Anniston Alabama 36207 —
Investigative Site Mesa Arizona 85210 —
Investigative Site Tucson Arizona 85712 —
Investigative Site Los Angeles California 90017 —
Investigative Site Rolling Hills Estates California 90274 —
Investigative Site Bradenton Florida 34208 —
Investigative Site Doral Florida 33126 —
Investigative Site Doral Florida 33166 —
Investigative Site Gainesville Florida 32607 —
Investigative Site Hialeah Florida 33012 —
Investigative Site Hialeah Florida 33013 —
Investigative Site Hialeah Florida 33016 —
Investigative Site Miami Florida 33032 —
Investigative Site Miami Florida 33125 —
Investigative Site Miami Florida 33126 —
Investigative Site Miami Florida 33135 —
Investigative Site Miami Florida 33144 —
Investigative Site Miami Florida 33155 —
Investigative Site Miami Florida 33175 —
Investigative Site Miami Florida 33176 —
Investigative Site Miami Florida 33180 —
Investigative Site North Miami Beach Florida 33169 —
Investigative Site Ormond Beach Florida 32174 —
Investigative Site Palmetto Bay Florida 33157 —
Investigative Sites Pembroke Pines Florida 33024 —
Investigative Site Pompano Beach Florida 33064 —
Investigative Site Tampa Florida 33614 —
Investigative Site Tampa Florida 33615 —
Investigative Site Atlanta Georgia 30318 —
Investigative Site Idaho Falls Idaho 83404 —
Investigative Site Mishawaka Indiana 46544 —
Investigative Site Sterling Heights Michigan 48126 —
Investigative Site Las Vegas Nevada 89113 —
Investigative Site The Bronx New York 10456 —
Investigative Site High Point North Carolina 27262 —
Investigative Site Mount Airy North Carolina 27030 —
Investigative Site Columbus Ohio 43215 —
Investigative Site Smithfield Pennsylvania 15478 —
Investigative Site Baytown Texas 77521 —
Investigative Site Forney Texas 75126 —
Investigative Site Houston Texas 77017 —
Investigative Site Houston Texas 77024 —
Investigative Site Houston Texas 77090 —
Investigative Site Laredo Texas 78041 —
Investigative Site Mesquite Texas 75149 —
Investigative Site Pharr Texas 78577 —
Investigative Site Kirkland Washington 98034 —
Investigative Site Seattle Washington 98109 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04913675, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 7, 2024 · Synced Nov 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.